The Wall Street Journal Names Acceleron to The Next Big Thing List of Top 50 Start-Ups in the United States

pan>)--Acceleron Pharma, Inc., a biopharmaceutical company developing protein
therapeutics for cancer and orphan diseases, today announced that it was
recognized by the Wall Street Journal as one of the top 50 private
venture-backed companies in the United States. This is the second time
that Acceleron was named to the list.
“Acceleron has recently made tremendous progress in
advancing our pipeline of clinical-stage biologics and will deliver
results from numerous Phase 2 clinical trials in 2013. The next 12
months will be a transformative period in the evolution of the company.”
Being recognized by the Wall Street Journal as one of the top 50
venture-backed companies in the U.S. is an honor and a great
acknowledgement of our incredible employees, Board and partners, as well
as the breakthrough science that serves as the foundation of our novel
pipeline of products, said John Knopf, Ph.D., Chief Executive Officer
of Acceleron. Acceleron has recently made tremendous progress in
advancing our pipeline of clinical-stage biologics and will deliver
results from numerous Phase 2 clinical trials in 2013. The next 12
months will be a transformative period in the evolution of the company.
Acceleron was selected for The Next Big Thing The Top 50
Venture-Backed Companies based on criteria including fundraising
success, recent growth in the companys value and the track record of
its founders and board members. The editorial staff of Dow Jones
VentureWire also reviewed and ranked the start-ups based on their
knowledge of the companies products, competition and financial
performance. There were 5,900 companies considered for the ranking.
About Acceleron
Acceleron is a privately-held biopharmaceutical company committed to
discover, develop, manufacture and commercialize novel protein
therapeutics for orphan diseases and cancer. Accelerons scientific
approach takes advantage of its unique insight to discover
first-in-class therapies based on the TGF- protein superfamily.
Acceleron utilizes proven biotherapeutic technologies and capitalizes on
the companys internal GMP manufacturing capability to advance its
therapeutic programs rapidly and efficiently. The investors in Acceleron
include Advanced Technology Ventures, Alkermes, Avalon Ventures,
Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed
Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and
Venrock. For further information on Acceleron, please visit www.acceleronpharma.com.

Information Source: Business Wire